BCAL Introduces Avantect Multi-Cancer Early Detection Test

• BCAL introduces Avantect Multi-Cancer test in Australia.
• Test covers eight cancer types and provides organ-of-origin signal.
• Initial rollout in Sydney and Melbourne, expanding nationally.

BCAL Diagnostics Ltd (ASX: BDX) has introduced the Avantect Multi-Cancer Early Detection Test in Australia, marking a significant advancement in early cancer detection. This blood-based test identifies signals associated with eight different cancers and provides a likely organ-of-origin signal. The initial launch is in Sydney and Melbourne, with plans for broader national expansion. The test covers lung, pancreatic, liver, ovarian, gastric, oesophageal, breast, and colorectal cancers. In a case-controlled validation study, the test demonstrated an overall sensitivity of 56.2% and specificity of 98.4% across all analyzed cancers.